Fedratinib - Impact Biomedicines

Drug Profile

Fedratinib - Impact Biomedicines

Alternative Names: SAR-302503; TG-101348

Latest Information Update: 05 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TargeGen
  • Developer Impact Biomedicines; Sanofi
  • Class Phenyl ethers; Pyrimidines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myelofibrosis
  • Phase II Essential thrombocythaemia; Polycythaemia vera
  • Discontinued Solid tumours

Most Recent Events

  • 29 Oct 2018 Celgene initiates an expanded access program for Myelofibrosis (In children, In adolescents, In adults, In the elderly) in USA (PO) (NCT03723148)
  • 12 Apr 2018 Impact Biomedicines has been acquired by Celgene Corporation
  • 07 Jan 2018 Celgene Corporation signs a definitive agreement for acquisition of Impact Biomedicines
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top